LATEST ALERTSIt looks like there will be no easy or quick solutions to addressing the data gaps the European Food Safety Authority (EFSA) requires to reach a conclusion on the safety of CBD as an ingestible ingredient
The European Food Safety Authority wants more safety data before it approves CBD products as novel food. This is what it wants to know, and why, along with a summary of the science on each point
Germany should plan ahead to avoid problems which have plagued governments that have already legalised recreational cannabis on top of medical cannabis
“It’s a myth that cannabis relieves pain,” declared the Daily Mail. But that is not what the study it was reporting said at all
While cannabis use is now legal in many US states, there is as yet no reliable test to determine whether, or how far, a user may be “under the influence”
Lausanne could become the second Swiss city after Basel to launch a recreational cannabis trial this year. But while Basel’s pilot will involve just 400 participants, Lausanne is aiming for triple that number
Companies are trying new ways to reach cannabinoid customers in severely restricted Australia, but they must be careful not to fall foul of strict guidelines that separate promoting from simply informing the public about prescription goods
A six-year study of young adult behaviour reveals that when and where cannabis use is legalised, young people’s use of alcoho. and tobacco drops – and so does the use, and misuse, of pain-relieving prescription drugs
Strangely, Brexit and then the Covid-19 pandemic have combined to create ideal conditions for the UK to potentially become a leader in psychedelics research
A widespread recall of cannabis concentrates sold for vaping at medical cannabis dispensaries in the US state of Pennsylvania has left patients with more questions than answers about who to trust
Members of the Argentina Chamber of Deputies approved a law on 5th May that would establish a legal framework for the production, sale and export of medical cannabis as well as industrial hemp, a decision president Alberto Fernández says could generate 10,000 jobs in the South American country
Clinical trials are investigating how CBD can improve menstrual health and treat conditions such as premenstrual syndrome (PMS) and perhaps even endometriosis
The most common reasons survey respondents gave for using CBD are for treating anxiety, managing chronic pain, and easing issues with skin conditions
Basel will start allowing the sale of recreational cannabis through local pharmacies at the end of the summer as the first Swiss city to win the approval of health authorities for the pilot project
Jamaica is attempting to make itself as synonymous with medical-grade psychedelics in the minds of researchers as it is with cannabis production in the minds of many
Is the current system of peer-reviewed journal publication the best way to get the best science on CBD and cannabis? There could be another way
This regulatory report analyses the different approaches taken by states over what restrictions they impose on medical cannabis products that patients can buy
Five years after German patients were first allowed to obtain medical cannabis, demand has risen sharply – but there are still some unanswered issues on policy and practice that lobbyists want addressed
Patients in Iowa who rely on supplies of medical cannabis are tightly restricted in how much they can have, and may face a long trip to get it from one of the few licensed dispensaries in the US state
The Canadian government is proposing changes to make it easier to conduct non-therapeutic cannabis research in the country and to foster more investigation into the development of cannabis products
While Big Pharma acquisitions of companies involved in the development of cannabinoid treatments are expected to to propel and expand cannabinoid treatment options, the overall impact of and interest in Big Pharma’s reach into the industry remains a matter of speculation
Scientists around the world are starting to look even further afield for potential uses of cannabis in medical applications, such as treating the symptoms of long Covid-19, Alzheimer’s-related agitation, and to alleviate the pain resulting from HIV
US firm 22nd Century Group plans to use its expertise in plant science, biotechnology and genetics to move further into cannabinoid production
This is an important year for positive legislation affecting cannabinoids across South America, though some depends on election results and all of it will take a few years to take effect
Costa Rican president Carlos Alvarado, who has supported the legalisation of cannabis throughout his administration, has partially vetoed a bill that would have legalised medicinal cannabis and industrial hemp
Research from scientists at the University of Oregon suggests that certain cannabinoids can stop the SARS-CoV-2 (Covid-19) virus from infecting cells. This may lead to future treatments
Lawsuits in the US have finally overturned the DEA’s requirement that researchers interested in studying cannabis could only purchase from one source, the University of Mississippi
Potential demand for rarer cannabinoids is prompting firms to explore other methods of manufacturing, such as biosynthesis and chemical synthesis, to give higher yields at lower cost
Colombian insurance providers must now cover the cost of medical cannabis prescriptions, a move that could represent a “billion-dollar shift” in the market – and perhaps lay down a marker for other countries
Colombia has joined a select few countries now demanding mandatory coverage of medical cannabis by health insurance providers
Desired end product and environmental factors are the two things best kept in mind when considering hemp varieties for different countries
New guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) on the use of real word data and evidence to support clinical trials could help cannabinoid products gain approval
The most common subject of recent warning letters from the US Food and Drug Administration (FDA) over unsubstantiated health claims was CBD products that were claimed to mitigate, prevent, treat, diagnose or cure Covid-19
“Intoxicating” will be the word to watch for and THC will be the main driver for developments in 2022, CBD-Intel predicts
If 2020 was the year in the waiting-room then 2021 was perhaps the year of the unfulfilled hype. As predicted, there was little movement in many of the major issues controlling the CBD market
Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.
"*" indicates required fields
Get 7 days of access to industry updates through our news analysis and regulatory alerts
"*" indicates required fields
